Is there a link between cellular senescence and multiple sclerosis (MS) progression? Several presentations at this year’s European Committee for Treatment and Research in Multiple Sclerosis 2025 (ECTRIMS 2025) conference, which ends today in Barcelona, addressed this question.

Aera Therapeutics Inc. has nominated AERA-109, a targeted in vivo CAR T therapy designed to treat multiple B cell-mediated autoimmune diseases, as the company’s first development candidate. AERA-109 leverages Aera’s proprietary targeted lipid nanoparticle (tLNP) delivery platform and CAR T technology.

Clarivate plc has unveiled the 2025 Citation Laureates. Widely considered a predictor of the Nobel Prizes, this recognition has highlighted the discovery of biomolecular condensates in chemistry and the innate immunity signaling pathway in physiology or medicine, as well as the identification of leukemia stem cells and ghrelin, the so-called hunger hormone.

Genfleet Therapeutics (Shanghai) Inc. debuted on the Hong Kong Stock Exchange on its second attempt at an IPO, raising HK$1.819 billion (US$234 million). Genfleet’s shares (HKEX:2595) rose to HK$44.00 at the opening bell on Sept. 19 and closed at HK$42.10, about 106% higher than the listing price.

GC Biopharma Corp. has filed an IND application with the South Korean Ministry of Food and Drug Safety (MFDS) for a phase I trial of GC-4006A, an mRNA vaccine candidate for COVID-19.

The FDA has cleared HDT Bio Corp.’s IND application for HDT-321, a first-in-class prophylactic designed to protect against Crimean-Congo hemorrhagic fever (CCHF).

Genfleet Therapeutics (Shanghai) Inc. debuted on the Hong Kong Stock Exchange on its second attempt at an IPO, raising HK$1.819 billion (US$234 million). Genfleet’s shares (HKEX:2595) rose to HK$44.00 at the opening bell on Sept. 19 and closed at HK$42.10, about 106% higher than the listing price.

With positive phase III results in hand, Roivant Sciences Ltd. and Priovant Therapeutics Inc. anticipate an NDA filing in the first half of 2026, seeking approval for brepocitinib, a dual inhibitor of tyrosine kinase 2 and JAK1, in dermatomyositis, a rare autoimmune disease with limited treatment options.

Dualitas Therapeutics Inc. exited stealth mode with a $65 million series A investment that was co-led by Versant Ventures and Qiming Venture Partners USA.